Grant Award Details
Develop optimized, defined, scalable 3D process for hESC-derived OPC
Grant Application Details
- Scalable, Defined Production of Oligodendrocyte Precursor Cells to Treat Neural Disease and Injury
The goal of this proposal is to develop an optimized, scalable process to manufacture high quality oligodendrocyte precursor cells (OPCs) from human pluripotent stem cells for treating human disease.
OPCs have therapeutic potential for spinal cord injury, restoration of cognitive function after cancer radiation therapy, inherited demyelinating disease, and potentially multiple sclerosis.
Major Proposed Activities
- To engineer human embryonic stem cell lines with fluorescent protein reporters to quantify differentiation into oligodendrocyte precursor cells (OPCs).
- To use a high throughput system to screen thousands of cell culture conditions and thereby optimize a chemically-defined three-dimensional culture for differentiation into OPCs.
- To validate the capacity of the differentiated oligodendrocyte precursor cells to remyelinate neurons in culture and in the nervous system.
- To scale up this cell manufacturing system in a bioreactor for future translation towards preclinical and clinical studies.
This proposal will accelerate the development of a stem cell therapy to treat patients with demyelinating conditions, a serious unmet medical need. Also, the PI has a strong record of translating research towards clinical development within industry, particularly within California. Finally, this project will expose young scientists within a large stem cell center to highly interdisciplinary training at the interface of science and engineering, thereby enhancing our California workforce.